



(11) **EP 0 946 539 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:

13.08.2003 Bulletin 2003/33

(21) Application number: **97954929.2**

(22) Date of filing: **15.12.1997**

(51) Int Cl.7: **C07D 333/34, C07D 295/135,
C07D 285/14, C07D 307/79,
C07D 215/36, C07D 209/30,
C07D 261/10, C07D 333/62,
C07D 211/70, C07D 409/04,
C07D 409/12**

(86) International application number:
PCT/EP97/07159

(87) International publication number:
WO 98/027081 (25.06.1998 Gazette 1998/25)

(54) **SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS
MEDICAMENTS**

**SULFONAMID-DERIVATE, VERFAHREN ZUR IHRER HERSTELLUNG UND IHRE VERWENDUNG
ALS ARZNEIMITTEL**

**DERIVES DE SULFAMIDE, PROCEDE DE PREPARATION DE CES DERIVES ET UTILISATION DE
CES DERNIERS EN TANT QUE MEDICAMENTS**

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**
Designated Extension States:
RO SI

(30) Priority: **19.12.1996 GB 9626377**
17.01.1997 GB 9700901
27.10.1997 GB 9722757

(43) Date of publication of application:
06.10.1999 Bulletin 1999/40

(73) Proprietor: **SmithKline Beecham plc**
Brentford, Middlesex TW8 9GS (GB)

(72) Inventors:
• **BROMIDGE, Steven Mark**
Harlow CM19 5AW (GB)
• **KING, Francis David**
Harlow Essex CM19 5AW (GB)

• **WYMAN, Paul Andrian**
Harlow Essex CM19 5AW (GB)

(74) Representative: **Waters, David Martin, Dr.**
GlaxoSmithKline
Corporate Intellectual Property (CN9.25.1)
980 Great West Road
Brentford, Middlesex TW8 9GS (GB)

(56) References cited:
EP-A- 0 021 580 EP-A- 0 076 072
EP-A- 0 533 267 EP-A- 0 558 999
EP-A- 0 609 734 WO-A-87/03782
WO-A-90/09787 WO-A-95/06637
WO-A-95/11243 WO-A-95/15954
WO-A-95/32967 US-A- 4 315 014

• **H. SAYO ET AL.: CHEMICAL AND
PHARMACEUTICAL BULLETIN, vol. 25, no. 4,
1977, pages 640-6, XP002064436**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


EP 0 946 539 B1

Description

[0001] This invention relates to compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.

[0002] EPA 0 021 580 and EPA 0 076 072 describe sulphonamide derivatives which are disclosed as having antiarrhythmic activity. A structurally distinct class of compounds has now been discovered, which have been found to have 5HT₆ receptor antagonist activity. 5HT₆ receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, cognitive memory enhancement e.g. for the treatment of Alzheimer's disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds of the invention are also expected to be of use in the treatment of certain GI (gastrointestinal) disorders such as IBS (Irritable Bowel Syndrome).

[0003] The present invention therefore provides, in a first aspect, a compound of formula (I) or a salt thereof:



wherein:

P is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur;

A is a single bond, a C₁₋₆alkylene or a C₁₋₆alkenylene group;

R¹ is halogen, C₁₋₆alkyl optionally substituted by one or more halogen atoms, C₃₋₆cycloalkyl, COC₁₋₆alkyl, C₁₋₆alkoxy, OCF₃, hydroxy, hydroxyc₁₋₆alkyl, hydroxyc₁₋₆alkoxy, C₁₋₆alkoxyc₁₋₆alkoxy, nitro, amino, C₁₋₆alkylamino or diC₁₋₆alkylamino, cyano or R¹ is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur;

n is 0, 1, 2, 3, 4, 5 or 6;

R² is hydrogen, C₁₋₆alkyl or aryl C₁₋₆alkyl;

R³ is a group R⁵ or together with R⁵ forms a group (CH₂)₂O or (CH₂)₃O or R³ is linked to R² to form a group (CH₂)₂ or (CH₂)₃;

R⁴ is an N-piperazine ring optionally substituted by C₁₋₆alkyl; and

R⁵ is hydrogen, halogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, COC₁₋₆alkyl, C₁₋₆alkoxy, hydroxy, hydroxyc₁₋₆alkyl, hydroxyc₁₋₆alkoxy, C₁₋₆alkoxyc₁₋₆alkoxy, nitro, trifluoromethyl, cyano or aryl;

wherein aryl represents phenyl or naphthyl.

[0004] C₁₋₆Alkyl groups, whether alone or as part of another group, may be straight chain or branched. Preferred alkyl groups are generally methyl and ethyl.

[0005] When P is a bicyclic heterocyclic ring suitable examples include benzothiophene, quinoline or isoquinoline. When P is a 5 to 7-membered heterocyclic ring suitable examples include thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrrolidinyl and pyrazinyl. The heterocyclic rings can be linked to the remainder of the molecule via any suitable carbon atom or, when present, a nitrogen atom.

[0006] Preferably P is phenyl, thiophene, benzothiophene or naphthyl.

[0007] Preferably A is a single bond, an ethylene group or a -CH=CH- group. Most preferably A is a single bond.

[0008] When R¹ is a heterocyclic group suitable examples include those listed above. Preferably R¹ is halogen or C₁₋₆alkyl optionally substituted by one or more halogen atoms, for example methyl or trifluoromethyl.

[0009] Preferably n is 0, 1, 2 or 3, particularly 1 or 2.

[0010] Suitably R² is hydrogen or C₁₋₆alkyl. Preferably R² is hydrogen.

[0011] It will be appreciated that when R³/R⁵ groups are linked together the two groups must be attached to adjacent

carbon atoms of the phenyl ring. Preferably R³ is a group R⁵, in particular hydrogen.

[0012] Preferably R⁴ is meta with respect to the sulphonamide linkage. Optional substituents for these rings, which can be present on carbon and/or nitrogen atoms, include, in particular methyl. More preferably R⁴ is unsubstituted piperazine.

5 [0013] Preferably R⁵ is C₁₋₆alkoxy, most preferably methoxy. Preferably R⁵ is para with respect to the sulphonamide linkage.

[0014] A preferred meaning for P-A is benzo[b]thiophen-2-yl or benzo[b]thiophen-3-yl optionally substituted by one or two R¹ groups, especially 5-chloro-3-methylbenzo[2]thiophen-2-yl.

[0015] Particular compounds of the invention include:

10

4-Bromo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-5-(pyridin-2-yl)-2-thiophenesulfonamide,
 2,5-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-thiophenesulfonamide,
 15 4-Bromo-5-chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3-Bromo-5-chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzylsulfonamide,
 2-Bromo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 20 3-Bromo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-methylbenzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-*trans*-styrenesulfonamide,
 3,4-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3,5-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 25 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-[2,1,3]benzothiadiazole-4-sulfonamide,
 5-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methyl-2-benzothiophenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methyl-5-nitrobenzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-trifluoromethylbenzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-trifluoromethylbenzenesulfonamide,
 30 2,5-Dimethoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide,
 4-Fluoro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-Iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-Ethyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 35 4-*tert*-Butyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-Isopropyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-*tert*-Amyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-trifluoromethoxybenzenesulfonamide,
 4-*n*-Butoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 40 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-methylbenzenesulfonamide,
 5-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1-naphthalenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-naphthalenesulfonamide,
 5-(Dimethylamino)-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1-naphthalenesulfonamide,
 45 4-Bromo-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]-benzenesulfonamide,
 4-Methoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-*n*-Butyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-Amino-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 2-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 50 3-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 2,3,4-Trichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide,
 4-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2,5-dimethylbenzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methylbenzenesulfonamide,
 2,5-Dibromo-3,6-difluoro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide,
 55 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2,3,5,6-tetramethylbenzenesulfonamide,
 5-Chloro-2-methoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide,
 3-Fluoro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3,4-Difluoro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,

4-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-nitrobenzenesulfonamide,
 3-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methylbenzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-8-quinolinesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-phenylbenzenesulfonamide,
 3,4-Dimethoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3,5-dimethyl-4-isoxazolesulfonamide,
 4-Bromo-N-[4-methoxy-3-(4-ethylpiperazin-1-yl)phenyl]benzenesulfonamide,
 2,3-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide,
 5-Iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methylbenzenesulfonamide,
 3-Iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3-Iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-methylbenzenesulfonamide,
 5-Chloronaphthalene-2-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 5-Chloronaphthalene-1-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 4-Chloronaphthalene-1-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 7-Chloronaphthalene-1-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 5-Chloro-2-methylbenzo[b]thiophene-3-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 Benzofuran-2-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 1-Methyl-1H-indole-2-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 5-Pyridin-2-ylthiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 N-(4-Methoxy-3-piperazin-1-ylphenyl)-3-trifluoromethylbenzenesulfonamide,
 3-Iodo-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 3,5-Dimethylisoxazole-4-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 3,5-Dichloro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 2,5-Dibromo-3,6-difluoro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 Naphthalene-1-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 2-Bromo-5-chlorothiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 2-Chloro-4-fluoro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 3-Bromo-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 3-Chloro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 5-Chloronaphthalene-2-sulfonic acid(4-methoxy-3-piperazin-1-ylphenyl)amide,
 4-Bromo-5-chlorothiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 2,5-Dichlorothiophene-3-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 4-Bromo-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 5-Chloro-2-methylbenzo[b]thiophene-3-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 1-Methyl-1H-indole-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 Benzofuran-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 Naphthalene-2-sulfonic acid(4-methoxy-3-piperazin-1-ylphenyl)amide,
 5-Chloronaphthalene-1-sulfonic acid(4-methoxy-3-piperazin-1-ylphenyl)amide,
 4-Chloro-2,5-dimethyl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 3,4-Dichloro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 3-Chloro-N-(4-methoxy-3-piperazin-1-ylphenyl)-4-methyl-benzenesulfonamide,
 2-Trifluoromethyl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 4-Iodo-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 4-tert-Butyl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 Naphthalene-1-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 Thiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 5-Chlorothiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 5-Pyridin-2-ylthiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 2,5-Dichlorothiophene-3-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 4-Bromo-5-chlorothiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 3-Bromo-5-chlorothiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 4-Chloro-2,5-dimethyl-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]
 amide,
 Naphthalene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide.
 3-Bromo-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide,
 3,5-Dichloro-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide,


4-*tert*-Butyl-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide,
 2,5-Dibromo-3,6-difluoro-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide,
 2,5-Dibromo-3,6-difluoro-N-(7-piperazin-1-yl-2,3-dihydrobenzofuran-5-yl)benzenesulfonamide,
 4-Chloro-2,5-dimethyl-N-(7-piperazin-1-yl-2,3-dihydrobenzofuran-5-yl)benzenesulfonamide,
 5-Chloro-3-methyl-benzo[b]thiophene-2-sulphonic acid [4-hydroxy-3-(4-methylpiperazin-1-yl)-phenyl]-amide,
 5-Chloro-3-methyl-benzo[b]thiophene-2-sulphonic acid [4-ethoxy-3-(4-methylpiperazin-1-yl)-phenyl]-amide,
 5-Chloro-3-methyl-benzo[b]thiophene-2-sulphonic acid [4-isopropoxy-3-(4-methylpiperazin-1-yl)-phenyl]-amide,
 Naphthalene-2-sulfonic acid [2-bromo-5-(4-methylpiperazin-1-yl)phenyl]amide
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [4-chloro-3-(4-methylpiperazin-1-yl)phenyl]amide,
 Naphthalene-2-sulfonic acid [4-bromo-3-(4-methylpiperazin-1-yl)phenyl]amide,
 1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-6-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indole,
 1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-5-methoxy-6-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indole
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid[4-methoxy-2-methyl-3-(4-methylpiperazin-1-yl)phenyl]
 amide,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid[2-(2-hydroxyethyl)-4-methoxy-3-(4-methylpiperazin-1-yl)
 phenyl]amide,
 1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-5-methoxy-4-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indole
 hydrochloride,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amide,
 Naphthalene-2-sulfonic acid [3-(4-methylpiperazin-1-yl)phenyl]amide and pharmaceutically acceptable salts
 thereof.

[0016] The compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceu-
 tically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric,
 lactic, mandelic, tartaric and methanesulphonic.

[0017] Compounds of formula (I) may also form solvates such as hydrates, and the invention also extends to these
 forms. When referred to herein, it is understood that the term 'compound of formula (I)' also includes these forms.


[0018] Certain compounds of formula (I) are capable of existing in stereoisomeric forms including diastereomers and
 enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including race-
 mates. The different stereoisomeric forms may be separated one from the other by the usual methods, or any given
 isomer may be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms
 and mixtures thereof.

[0019] The present invention also provides a process for the preparation of a compound of formula (I) or a pharma-
 ceutically acceptable salt thereof, which process comprises the coupling of a compound of formula (II):



(II)

in which R¹, n, P, and A are as defined in formula (I) or protected derivatives thereof and L is a leaving group with a
 compound of formula (III):



(III)

in which R², R³, R⁴ and R⁵ are as defined in formula (I) or protected derivatives thereof and optionally thereafter:

- removing any protecting groups,
- interconverting compounds of formula (I) wherein R⁴ represents NH-piperazine to compounds of formula (I) wherein R⁴ represents N-C₁₋₆ alkyl-piperazine by alkylation,
- forming a pharmaceutically acceptable salt.

[0020] Suitable leaving groups include halogen, in particular chloro. The reaction of a compounds of formulae (II) and (III) is carried out by mixing the two reagents together, optionally in an inert solvent such as acetone. Such a reaction may be carried out in the presence of base.

[0021] Those skilled in the art will appreciate that it may be necessary to protect certain groups. Suitable protecting groups and methods for their attachment and removal are conventional in the art of organic chemistry, such as those described in Greene T.W. 'Protective groups in organic synthesis' New York, Wiley (1981). For example, suitable protecting groups for the piperazine group include BOC, COCCl₃, COCF₃ and methyl the latter of which may be removed by treatment with 1-chloroethyl chloroformate according to standard procedures.

[0022] N-substituted piperazines can be prepared by alkylation of the appropriate NH-piperazine compound according to standard procedures.

[0023] Compounds of formulae (II) and (III) are commercially available or may be prepared according to known methods or analogous to known methods.

[0024] Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.

[0025] Compounds of formula (I) and their pharmaceutically acceptable salts have 5HT₆ receptor antagonist activity and are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease (cognitive memory enhancement), sleep disorders (including disturbances of Circadian Rhythm), feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds of the invention are also expected to be of use in the treatment of certain GI disorders such as IBS

[0026] Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders.

[0027] The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0028] In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of the above disorders.

[0029] The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0030] A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

[0031] Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

[0032] Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.

[0033] For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

[0034] The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active

material, depending on the method of administration.

[0035] The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.5 to 100 mg; and such therapy may extend for a number of weeks or months.

[0036] When administered in accordance with the invention, no unacceptable toxicological effects are expected with the compounds of the invention.

[0037] The following Descriptions and Examples illustrate the preparation of compounds of the invention.

Description 1

1-(2-Methoxy-5-nitrophenyl)piperazine (D1)

[0038] A solution of 5M sulphuric acid (114ml) was added over 0.3h to 1-(2-methoxyphenyl)piperazine (110g) at 0°C with stirring. To the ice-cooled stirred slurry was then added, over 1.75h, concentrated sulphuric acid (560ml) and the temperature was maintained for a further 1.5h. Potassium nitrate (71.5g) was then added portionwise over 1.5h to the stirred, cold, viscous mixture which was then left to stand for 18h. The solution was poured onto ice (2Kg) and the resulting cooled mixture brought to pH 12 by the addition of 40% sodium hydroxide solution. The oily mixture was extracted with ethyl acetate (2 x 2L) and the combined organic extracts were washed with water (3L), dried (Na₂SO₄), concentrated to a residue which was stirred with diethyl ether (700ml) to give the title compound (D1) as a yellow solid, m.p. 84-87°C (95g, 70%). MH⁺238.

Description 2

4-*tert*-Butoxycarbonyl-1-(2-methoxy-5-nitrophenyl)piperazine (D2)

[0039] To a stirred heterogeneous solution of 1-(2-methoxy-5-nitrophenyl)piperazine (D1) (99.2g) in tetrahydrofuran (1.1L) and water (1.1L) was added a solution of di-*tert*-butyldicarbonate (91.3g) in tetrahydrofuran (300ml) over 0.5h. Potassium carbonate (60.7g) was then added in portions over 0.5h and the mixture was stirred at ambient temperature for 18h. The whole was concentrated to remove the organic solvent and the resulting mixture was extracted with dichloromethane (2 x 1L). The combined organic phases were washed with water (1L), dried (Na₂SO₄) and concentrated to a residue which was stirred with diethyl ether (500ml) and hexane (750ml) to afford the title compound (D2) as a yellow solid, m.p. 136-7°C (125g, 89%). MH⁺338.

Description 3


4-*tert*-Butoxycarbonyl-1-(5-amino-2-methoxyphenyl)piperazine (D3)

[0040] A slurry of 10% palladium on carbon (10g) in a solution of 4-*tert*-butoxycarbonyl-1-(2-methoxy-5-nitrophenyl)piperazine (D2) (124.5g) in ethanol (3.5L) and water (50ml) was stirred with hydrogen at ambient temperature and atmospheric pressure for 18h. The reaction mixture was filtered and the filtrate concentrated to afford the title compound (D3) as a gum (112g, 99%). MH⁺ 308.

Description 4-14

General Preparation of N-[4-methoxy-3-(4-*t*-butoxycarbonyl-1-piperazinyl)phenyl] arylsulfonamides (D4-D14)

[0041] A solution of 4-*t*-butoxycarbonyl-1-(5-amino-2-methoxyphenyl)piperazine (D3) (15.6mmol), diisopropylethylamine (15.6mmol) and the appropriate aryl sulfonyl chloride (15.6mmol) in dichloromethane (100ml) was stirred at room temperature for 18h. The mixture was concentrated and the residue chromatographed on silica gel eluting with a dichloromethane/methanol gradient to give the following pure title products.

5		MS(MH ⁺)
10	2-Chloro-4-fluoro-N-[4-methoxy-3-(4- <i>t</i> -butoxycarbonyl)-1-piperazinyl]phenyl]benzenesulfonamide (D4)	*
15	3-Bromo-N-[4-methoxy-3-(4- <i>t</i> -butoxycarbonyl)-1-piperazinyl]phenyl]benzenesulfonamide (D5)	*
20	3-Chloro-N-[4-methoxy-3-(4- <i>t</i> -butoxycarbonyl)-1-piperazinyl]phenyl]benzenesulfonamide (D6)	*
25	4-Bromo-5-chlorothiophene-2-sulfonic acid [4-methoxy-3-(4- <i>t</i> -butoxycarbonyl)-1-piperazinyl]phenyl] amide (D7)	*
30	2,5-Dichlorothiophene-3-sulfonic acid [4-methoxy-3-(4- <i>t</i> -butoxycarbonyl)-1-piperazinyl]phenyl]amide (D8)	*
35	4-Bromo-N-[4-methoxy-3-(4- <i>t</i> -butoxycarbonyl)-1-piperazinyl]phenyl]benzenesulfonamide (D9)	526/528
40	5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [4-methoxy-3-(4- <i>t</i> -butoxycarbonyl)-1-piperazinyl]phenyl] amide (D10)	552/554
45	5-Chloro-2-methylbenzo[b]thiophene-3-sulfonic acid [4-methoxy-3-(4- <i>t</i> -butoxycarbonyl)-1-piperazinyl]phenyl] amide (D11)	552/554
	Benzofuran-2-sulfonic acid [4-methoxy-3-(4- <i>t</i> -butoxycarbonyl)-1-piperazinyl]phenyl] amide (D12)	488
	1-Methyl-1H-indole-2-sulfonic acid [4-methoxy-3-(4- <i>t</i> -butoxycarbonyl)-1-piperazinyl]phenyl] amide (D13)	501
	5-Chloronaphthalene-2-sulfonic acid [4-methoxy-3-(4- <i>t</i> -butoxycarbonyl)-1-piperazinyl]phenyl]amide (D14)	*

* Intermediate used crude without isolation

50 Description 10

5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [4-methoxy-3-(4-*tert*-butoxycarbonyl)piperazin-1-yl]phenyl]amide (D10)

55 [0042] Pyridine (60ml) was added to a stirred solution of 4-*tert*-butoxycarbonyl-1-(5-amino-2-methoxyphenyl)piperazine (D3) (112g) in dichloromethane (1L) at ambient temperature under argon. To this solution was added over 0.75h a solution of 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl chloride (102.5g) in dichloromethane (2.1L) and the purple solution was stirred for 18h. The mixture was then washed with 1M hydrochloric acid solution (3L), water (3L), dried

(Na₂SO₄), and concentrated to a foam which was stirred with acetone (800ml) and water (800ml) to afford the title compound (D10) as a maroon solid, m.p. 100-103°C (194.9g, 97%). MH⁺ 552/554.

Description 15

1-(2-Methoxy-5-nitrophenyl)-4-trichloroacetyl piperazine (D15)

[0043] A solution of 5-nitro-1-(2-methoxyphenyl)piperazine (D1) (44g) in dichloromethane (300ml) was added to a stirred solution of trichloroacetyl chloride (32ml) in dichloromethane (200ml) over 0.25h. After 3hrs, the reaction mixture was concentrated and the residue recrystallised from chloroform to yield the title compound (D15) as a yellow solid (43g, 61%). Found MH⁺ 382/384.

Description 16

1-(5-Amino-2-methoxyphenyl)-4-trichloroacetyl piperazine (D16)

[0044] A solution of stannous chloride dihydrate (27g) in concentrated HCl (60ml) was slowly added to a stirred suspension of 1-(2-methoxy-5-nitrophenyl)-4-trichloroacetyl piperazine (D15) (15g) in concentrated HCl/ethanol (1:2, 120ml). After 24hrs, the mixture was filtered, diluted with dichloromethane (600ml) and basified with Na₂CO₃ solution. The layers were separated, the organic phase dried, concentrated to 1/3 the volume and acidified with 1M ethereal HCl solution to afford the title compound (D16) as a green solid (2.5g, 15%). Found MH⁺ 352.

Description 17

Cyclopropyl-[4-(2-methoxy-5-nitrophenyl)-piperazin-1-yl]methanone (D17)

[0045] To a solution of 1-(2-methoxy-5-nitrophenyl)-piperazine (500mg, 2.1mmol) in dichloromethane (50ml) at 0°C under argon was added triethylamine (0.59ml, 4.2mmol) and cyclopropane carbonyl chloride (2.1mmol). Stirring was continued for 12 hrs. The reaction mixture was concentrated *in vacuo* and partitioned between saturated aqueous NaHCO₃ and dichloromethane. The organic layer was dried over sodium sulphate and concentrated *in vacuo* to give the title compound (D17) in 90% yield. Found MH⁺ 306.

Description 18

[4-(2-Methoxy-5-nitrophenyl)-piperazin-1-yl]phenyl methanone (D18)

[0046] The title compound was prepared in 85% yield using the procedure outlined in D17 using benzoyl chloride. Found MH⁺ 342.

Description 19

[4-(5-Amino-2-methoxy-phenyl)-piperazin-1-yl]cyclopropyl methanone (D19)

[0047] A solution of the cyclopropyl-[4-(2-methoxy-5-nitrophenyl)-piperazin-1-yl]methanone (D17) (1.8mmol) in ethanol was hydrogenated over 10% Palladium on charcoal catalyst for 2hrs at room temperature to give the title compound in 91% yield. Found MH⁺ 276.

Description 20

[4-(5-Amino-2-methoxy-phenyl)-piperazin-1-yl]phenyl methanone (D20)

[0048] The title compound was prepared in 95% yield using the procedure outlined in D19. Found MH⁺ 312

Description 26

1-(4-Bromo-3-nitrophenyl)-4-methyl piperazine (D26)

[0049] A solution of 1-methyl-4-(3-nitrophenyl)piperazine (EP0533267A) (1.0g; 4.5 mmol) in glacial acetic acid (25

ml) was treated with bromine (0.23 ml; 1 equivalent). The reaction mixture was stirred at 75° overnight, then cooled, filtered, and the yellow sticky solid was partitioned between potassium carbonate (aq) and 2% methanol in dichloromethane. The organic phase was dried (Na₂SO₄) and evaporated under reduced pressure to leave the title compound (D26) as a viscous orange oil (928 mg, 68%) MH⁺=300/302.

Description 27

2-Bromo-5-(4-methylpiperazin-1-yl)phenylamine (D27)

[0050] A suspension of iron powder (1.77g, 31.6 mmol) in saturated aqueous ammonium chloride solution (140 ml) at 100°C, was treated dropwise with a solution of 1-(4-bromo-3-nitrophenyl)-4-methylpiperazine (D26) (3.54g, 11.8 mmol) in methanol (70 ml). The mixture was refluxed for a further 1h, and was then cooled and partitioned between water and 3% methanol in dichloromethane. The organic phase was dried (Na₂SO₄) and evaporated under reduced pressure to give the crude product. This was purified by chromatography on silica gel, eluting with methanol and dichloromethane to give the title compound (D27) as a white solid (2.18g, 68%) MH⁺=270/272.

Description 28

2-Methoxy-6-methylphenylamine (D28)

[0051] A solution of 1-methoxy-3-methyl-2-nitrobenzene (15.04g, 0.09 mol) in ethanol (250 ml) was hydrogenated over 10% palladium on charcoal (4g) at atmospheric pressure and at room temperature, for 18h. The catalyst was removed by filtration, and the filtrate evaporated under reduced pressure to leave the title compound (D28) as an amber oil, which crystallised on standing (11.18g, 91%).
¹H NMR (250 MHz, CDCl₃) δ (ppm): 6.75-6.65 (m, 3H), 3.81 (s, 3H), 3.72 (br s, 2H), 2.19 (s, 3H).

Description 29

1-(2-Methoxy-6-methylphenyl)-4-methylpiperazine (D29)

[0052] A mixture of 2-methoxy-6-methylphenylamine (D28) (3.62g, 26.4 mmol), mechlorethamine hydrochloride (12.7g, 66 mmol) and potassium carbonate (15g) in chlorobenzene (90 ml) was refluxed under argon for 20 h. The mixture was cooled and filtered, and the filtrate evaporated under reduced pressure to leave the title compound (D29) as a red oil which slowly crystallised on standing (5.4g, 93%) MH⁺=221.

Description 30

1-(6-Methoxy-2-methyl-3-nitrophenyl)-4-methylpiperazine (D30)

[0053] A solution of 1-(2-methoxy-6-methylphenyl)-4-methylpiperazine (D29) (6.2g, 28 mmol) in concentrated sulfuric acid (50 ml) was treated portionwise with potassium nitrate (3.3g, 33 mmol) over 5 mins, maintaining the temperature at 25-30°C. The mixture was stirred overnight at room temperature, then added to ice, and basified with 40% sodium hydroxide solution. The mixture was extracted with dichloromethane and the organic phase was dried (Na₂SO₄) and evaporated under reduced pressure to give crude compound. Purification by chromatography on silica gel eluting with methanol and dichloromethane afforded the title compound (D30) (4.56g, 61%) MH⁺=266.

Description 31

2-[3-Methoxy-2-(4-methylpiperazin-1-yl)-6-nitrophenyl]ethanol (D31)

[0054] A mixture of 1-(6-methoxy-2-methyl-3-nitrophenyl)-4-methylpiperazine (D30) (360 mg, 1.36 mmol), dry dimethylsulfoxide (3 ml), paraformaldehyde (82 mg, 2.72 mmol) and potassium tert-butoxide (52 mg, 0.46 mmol) was heated at 70-75°C for 30 h. After cooling, the mixture was partitioned between water and ethyl acetate. The organic phase was dried (Na₂SO₄) evaporated under reduced pressure and purified by chromatography on silica gel, eluting with methanol and dichloromethane, to give the title compound (D31) as a yellow solid (152 mg, 38%) MH⁺=296.

Description 32

2-[6-Amino-3-methoxy-2-(4-methylpiperazin-1-yl)phenyl]ethanol (D32)

5 [0055] The title compound (D32) was prepared from 2-[3-methoxy-2-(4-methylpiperazin-1-yl)-6-nitrophenyl]ethanol (D31) (142 mg, 0.48 mmol) using the method of Description 28 as a clear oil which crystallised on standing (94mg, 74%) $MH^+ = 266$.

Description 33

10

4-Methoxy-2-methyl-3-(4-methylpiperazin-1-yl)phenylamine (D33)

[0056] The title compound (D33) was prepared from 1-(6-methoxy-2-methyl-3-nitrophenyl)-4-methylpiperazine (D30) (150 mg, 0.56 mmol) using the method of Description 28 as a tan powder (78 mg, 59%) $MH^+ = 236$.

15

Description 34

1-(2-Methoxy-4-nitrophenyl)-4-methylpiperazine (D34)

20

[0057] A mixture of N-methylpiperazine (216 mg, 2.15 mmol), 2-bromo-5-nitroanisole (1g, 4.3 mmol), potassium carbonate (447 mg, 3.23 mmol), copper (I) bromide (86.6 mg, 0.30 mmol) in pyridine (0.5 ml) and toluene (2 ml) was heated at 100° C overnight. After cooling, the mixture was partitioned between water and ether and the aqueous phase was further extracted with ethyl acetate. The combined organic phases were dried (Na_2SO_4) and evaporated under reduced pressure, to give the crude product. This was purified by chromatography on silica gel, eluting with methanol and dichloromethane, to give the title compound (D34) as a yellow/brown oil (80 mg, 15%) $MH^+ = 252$.

25

Description 35

3-Methoxy-4-(4-methylpiperazin-1-yl)phenylamine (D35)

30

[0058] The title compound (D35) was prepared from 1-(2-methoxy-4-nitrophenyl)-4-methylpiperazine (D34) (80mg, 0.319 mmol) using the method of Description 28 (50 mg, 71%) $MH^+ = 222$.

General preparation of aryl-N-(4-methoxy-3-piperazin-1-yl)-benzenesulfonamide hydrochlorides on solid phase

35

Description 40

Preparation of 1-(2-methoxy-5-nitrophenyl)piperazin-4-yl bound to Merrifield resin

40

[0059] A solution of 1-(2-methoxy-5-nitrophenyl)piperazine (9.7g) in N-methylpyrrolidin-2-one (NMP) (150ml) was heated with chloromethylpolystyrene-divinylbenzene resin (Merrifield, 150-300 mesh) at 60°C for 24h under argon. The resin was then filtered, washed (NMP; dichloromethane/methanol gradient) and dried to give the title compound (6.9g) which was used directly in Description 41.

45

Description 41

Preparation of 1-(5-amino-2-methoxyphenyl)piperazin-4-yl bound to Merrifield resin

50

[0060] A solution of stannous chloride dihydrate (9g) in N,N-dimethylformamide (DMF) (120ml) was stirred for 72h at room temperature under argon with the resin from Description 40 (6.9g). The resin was filtered, washed (DMF; dichloromethane/methanol gradient) and dried to give the title compound (6.6g) which was used directly in Description 42.

55

Description 42

General preparation of aryl-N-(4-methoxy-3-(4-polymeryl)piperazin-1-yl)-benzenesulfonamide bound to Merrifield resin


[0061] A solution of aryl sulfonyl chloride (0.4mmol) and di-isopropylethylamine (1mmol) in dichloromethane (3ml) was agitated for 24h at room temperature with the resin (0.1 mmol) from Description 41. The resin was then filtered, washed (dichloromethane; dichloromethane/methanol gradient; methanol) to yield the title compound which was used directly in Examples 133-137.

Example 1

N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]thiophene-2-ylsulfonamide

[0062] A solution of thiophene-2-sulfonyl chloride (82mg;0.45mmol) in acetone (2ml) was added to a solution of 4-methoxy-3-(4-methylpiperazin-1-yl)aniline (100mg;0.45mmol) in acetone (2ml) and the mixture stood overnight at room temperature. The resultant crystalline solid was filtered off and washed with acetone, then diethyl ether, to afford the title compound as the hydrochloride salt. (153mg;84%). MS: m/z = 368.

[0063] The following compounds were prepared in a similar manner.

	MS (MH ⁺)
4-Bromo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E2)	441
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophenesulfonamide (E3)	368
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-5-(pyridin-2-yl)-2-thiophenesulfonamide (E4)	445
2,5-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-thiophenesulfonamide (E5)	436/438
4-Bromo-5-chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophenesulfonamide (E6)	482
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E7)	362
3-Bromo-5-chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophenesulfonamide (E8)	480/482
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzylsulfonamide (E9)	376
2-Bromo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E10)	440/442
3-Bromo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E11)	440/442
3-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-methyl-benzenesulfonamide (E12)	410
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]- <i>trans</i> -styrenesulfonamide (E13)	388
3,4-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E14)	430
3,5-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E15)	430/432
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-[2,1,3]benzothiadiazole-4-sulfonamide (E16)	420
5-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methyl-2-benzothiophenesulfonamide (E17)	466

5	N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methyl-5-nitro-benzenesulfonamide (E18)	421
	N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-trifluoromethyl-benzenesulfonamide (E19)	430
10	N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-trifluoromethyl-benzenesulfonamide (E20)	430
	2,5-Dimethoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide (E21)	422
15	4-Fluoro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E22)	380
	4-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E23)	396
20	4-Iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E24)	488
	4-Ethyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E25)	390
25	4- <i>tert</i> -Butyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide (E26)	418
30	4-Isopropyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E27)	404
	4- <i>tert</i> -Amyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E28)	432
35	N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-trifluoromethoxy-benzenesulfonamide (E29)	446
	4- <i>n</i> -Butoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E30)	434
40	N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-methylbenzenesulfonamide (E31)	376
45	5-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophenesulfonamide (E32)	402
	N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1-naphthalenesulfonamide (E33)	412
50	N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-naphthalenesulfonamide (E34)	412
	5-(Dimethylamino)-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1-naphthalenesulfonamide (E35)	455
55	4-Bromo-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-	452/454

	yl]-benzenesulfonamide (E36)	
5	4-Methoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E37)	392
	4-n-Butyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E38)	418
10	4-Amino-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide (E39)	377
	2-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E40)	396
15	3-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide (E41)	396
	2,3,4-Trichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide (E42)	464/466
20	4-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2,5-dimethyl-benzenesulfonamide (E43)	424
25	N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methylbenzenesulfonamide (E44)	376
	2,5-Dibromo-3,6-difluoro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide (E45)	556
30	N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2,3,5,6-tetramethyl-benzenesulfonamide (E46)	418
	5-Chloro-2-methoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide (E47)	426
35	3-Fluoro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E48)	380
	3,4-Difluoro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E49)	398
40	4-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-nitro-benzenesulfonamide (E50)	441
45	3-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methyl-benzenesulfonamide (E51)	410
	N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-8-quinolinesulfonamide (E52)	413
50	N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-phenylbenzenesulfonamide (E53)	438
55	3,4-Dimethoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide (E54)	374

5	N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3,5-dimethyl-4-isoxazolesulfonamide (E55)	381
	4-Bromo-N-[4-methoxy-3-(4-ethylpiperazin-1-yl)phenyl]benzenesulfonamide (E56)	454/456
10	2,3-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide (E57)	430
	5-Iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methyl-benzenesulfonamide (E58)	502
15	3-Iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide (E59)	488
20	3-Iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-methyl-benzenesulfonamide (E60)	502
	5-Chloronaphthalene-2-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide (E61)	446
25	5-Chloronaphthalene-1-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide (E62)	446
30	4-Chloronaphthalene-1-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide (E63)	446
	7-Chloronaphthalene-1-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide (E64)	446
35	5-Chloro-2-methylbenzo[b]thiophene-3-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide (E65)	466
	Benzofuran-2-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide (E66)	402
40	1-Methyl-1H-indole-2-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide (E67)	415
45	2,3-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide (E138)	430/432

Preparation of Aryl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzene sulfonamides


[0064] These compounds were prepared using one of the three general methods as outlined below.

General Method 1

[0065] Examples 68-75 were prepared by the following general method from the corresponding N-methyl piperazine analogues:

[0066] A solution of 1-chloroethylchloroformate (1.7mmol) and the appropriate N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-arylsulfonamide (0.34mmol) in 1,2-dichloroethane (4ml) was refluxed for 0.75h, cooled, diluted with diisopropylethylamine (1.7mmol) and refluxed for a further 2.5hrs. The solution was concentrated to a residue which was re-dissolved in methanol, refluxed for 1hr and then stirred at room temperature for 24h. The mixture was concentrated,


and the residue partitioned between ethyl acetate and aqueous sodium bicarbonate solution. The organic layer was dried, concentrated to a residue and purified by column chromatography on silica gel using a methanol/dichloromethane solvent gradient. The hydrochloride salt of the product was prepared by dissolving the pure material from chromatography in acetone/dichloromethane and acidifying with ethereal HCl.

	MS(MH ⁺)
5-Pyridin-2-ylthiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide (E68)	431
N-(4-Methoxy-3-piperazin-1-ylphenyl)-3-trifluoromethylbenzenesulfonamide (E69)	416
3-Iodo-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide (E70)	474
3,5-Dimethylisoxazole-4-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide (E71)	367
3,5-Dichloro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide (E72)	416/418
2,5-Dibromo-3,6-difluoro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide (E73)	542
Naphthalene-1-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide (E74)	398
2-Bromo-5-chlorothiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide (E75)	466/468

General Method 2

[0067] Examples 76-86 were prepared by the following general method from the appropriate N-Boc derivative (D4-D14):

[0068] A stirred solution of the appropriate N-Boc derivative (D4-D14) (10.3mmol) in methanol (100ml) and 1M ethereal HCl (51.6ml) was heated at 60°C for 1.5h. The mixture was then concentrated and the residue stirred with acetone to afford the following title compounds as the hydrochloride salts.

5		MS(MH ⁺)
10	2-Chloro-4-fluoro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide (E76)	400/402
15	3-Bromo-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide (E77)	426/428
20	3-Chloro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide (E78)	382/384
25	5-Chloronaphthalene-2-sulfonic acid(4-methoxy-3-piperazin-1-ylphenyl)amide (E79)	432/434
30	4-Bromo-5-chlorothiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide (E80)	466/468
35	2,5-Dichlorothiophene-3-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide (E81)	422/424
40	4-Bromo-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide (E82)	426
	5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide (E83)	452
	5-Chloro-2-methylbenzo[b]thiophene-3-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide (E84)	452
	1-Methyl-1H-indole-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide (E85)	401
	Benzofuran-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide (E86)	388

Example 83


45 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl)amide hydrochloride (E83)

50 [0069] A stirred suspension of 5-chloro-3-methylbenzo[b]thiophene-2-sulfonic acid (4-methoxy-3-(4-*tert*-butoxycarbonylpiperazin-1-yl)phenylamide (D10) (193g) in tetrahydrofuran (820ml) and concentrated hydrochloric acid (180ml) was heated at reflux for 1.75h after which time a solution was obtained. The solution was concentrated and the residue dissolved in hot ethanol (600ml). Upon cooling, a solid precipitated which was filtered and recrystallised (ethanol/water 1:1) to give the title compound (E83) as a white solid, m.p. 276-280°C (dec.) (142g, 83%). δ_H (250 MHz, D₆-dmso) 2.29 (3H, s), 2.90 (4H, br s), 3.01 (4H, br s), 3.55 (3H, s), 6.54-6.71 (3H, m), 7.42 (1H, d, J 8.8Hz), 7.85 (1H, s), 7.93 (1H, d, J 8.8Hz), 9.03 (2H, br s), 10.3 (1H, br s). MH⁺ 452.

General Method 3


55 [0070] Examples 87-94 were prepared by the following general method:

[0071] A solution of the appropriate arylsulfonyl chloride (0.47mmol) and the aniline from D16 (0.47mmol) in dichloromethane (4ml) and pyridine (2.4mmol) was stirred for 18h at room temperature. The mixture was washed with 1M aqueous HCl then water. The layers were separated and to the organic one was added 4.4M aqueous KOH (1.4mmol) with vigorous stirring for 18h. To the heterogeneous mixture was then added an equal volume of 10% phosphate buffer. The layers were again separated and the organic phase was dried and diluted with 1M ethereal HCl to afford the hydrochloride salts of the following compounds as a precipitate.


	MS(MH ⁺)
Naphthalene-2-sulfonic acid(4-methoxy-3-piperazin-1-ylphenyl)amide (E87)	398
5-Chloronaphthalene-1-sulfonic acid(4-methoxy-3-piperazin-1-ylphenyl)amide (E88)	432/434
4-Chloro-2,5-dimethyl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide (E89)	410/412
3,4-Dichloro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide (E90)	416/418
3-Chloro-N-(4-methoxy-3-piperazin-1-ylphenyl)-4-methylbenzenesulfonamide (E91)	396/398
2-Trifluoromethyl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide (E92)	416
4-Iodo-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide (E93)	474
4-tert-Butyl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide (E94)	404

Examples 95-108

[0072] The dihydrobenzofuran derivative, below,




was prepared as described previously WO 95/11243 (Glaxo) and coupled with the appropriate aryl sulfonyl chlorides in the manner described in Example 1 to afford the following compounds:

5		MS(MH ⁺)
10	Naphthalene-1-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide (E95)	424
15	Thiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide (E96)	380
20	5-Chlorothiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide (E97)	414/416
25	5-Pyridin-2-ylthiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide (E98)	457
30	2,5-Dichlorothiophene-3-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide (E99)	448/450
35	4-Bromo-5-chlorothiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide (E100)	492/494
40	3-Bromo-5-chlorothiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide (E101)	492/494
45	4-Chloro-2,5-dimethyl-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide (E102)	436
50	5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide (E103)	478
55	Naphthalene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide (E104)	424
	3-Bromo-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide (E105)	452/454
	3,5-Dichloro-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide (E106)	442/444
	4- <i>tert</i> -Butyl-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide (E107)	430
	2,5-Dibromo-3,6-difluoro-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide (E108)	568

Examples 109-110

[0073] The following compounds were prepared from the corresponding N-methyl analogues by the general method

described for Examples 68-75:

	MS(MH ⁺)
2,5-Dibromo-3,6-difluoro-N-(7-piperazin-1-yl-2,3-dihydrobenzofuran-5-yl)benzenesulfonamide (E109)	554
4-Chloro-2,5-dimethyl-N-(7-piperazin-1-yl-2,3-dihydrobenzofuran-5-yl)benzenesulfonamide (E110)	422

Example 113

5-Chloro-3-methyl-benzo[b]thiophene-2-sulphonic acid [4-hydroxy-3-(4-methylpiperazin-1-yl)-phenyl]-amide (E113)

[0074] To a suspension of boron tribromide dimethyl sulphide complex (620mg, 2mmol) in 1,2 dichloroethane (30ml) under argon was added 5-chloro-3-methylbenzo[b]thiophene-2-sulphonic acid [4-methoxy-3-(4-methyl-piperazin-1-yl) phenyl]amide (E17) (0.2mmol). The reaction mixture was heated to reflux for 12hrs, cooled, quenched by the addition of water (20ml) and partitioned between saturated aqueous sodium bicarbonate and dichloromethane. The organic phase was dried over sodium sulphate and concentrated *in vacuo*. The residue was purified by chromatography on silica gel to afford the title compound (E113). Found MH⁺ 452 / 454

General Method for the Preparation of Examples 115-116

[0075] A solution of 5-chloro-3-methyl-benzo[b]thiophene-2-sulphonic acid [4-hydroxy-3-(4-methyl-piperazin-1-yl)-phenyl]-amide (E113) (100mg, 0.22mmol) and 18-Crown-6 (58mg, 0.22mmol) in DMF (0.5ml) was added to potassium hydride (35% dispersion in mineral oil, 50mg, 0.44mol) at room temperature under argon. After 10minutes a solution of the alkylating agent (0.22mmol) in DMF (0.3ml) was added and stirring was continued for 12 hrs. The reaction mixture was quenched with water and then concentrated *in vacuo* before partitioning between saturated aqueous sodium bicarbonate and dichloromethane. The organic phase was dried over sodium sulphate and concentrated *in vacuo*. The residue was purified by chromatography on silica to afford the following alkylated final compounds.

Example 115

5-Chloro-3-methyl-benzo[b]thiophene-2-sulphonic acid [4-ethoxy-3-(4-methylpiperazin-1-yl)-phenyl]-amide (E115)

[0076] Prepared in 28% yield using the procedure outlined above using ethyl iodide. Found MH⁺ 480 / 482.

Example 116

5-Chloro-3-methyl-benzo[b]thiophene-2-sulphonic acid [4-isopropoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-amide (E116)

[0077] Prepared in 20% yield using the procedure outlined above using 2-iodopropane. Found MH⁺ 494 / 496.

Example 118

Naphthalene-2-sulfonic acid [2-bromo-5-(4-methylpiperazin-1-yl)phenyl]amide (E118)

[0078] The title compound (E118) was prepared from naphthalene-2-sulfonyl chloride (100 mg, 0.44 mmol) and 2-bromo-5-(4-methylpiperazin-1-yl)phenylamine (D27) (120 mg, 0.44 mmol) using the method of Example 1 (85 mg, 35%)

MH⁺=460/462.

Example 119

5 **5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [4-chloro-3-(4-methylpiperazin-1-yl)phenyl]amide (E119).**

[0079] The title compound (E119) was prepared from 4-chloro-3-(4-methylpiperazin-1-yl)benzenamine (EP 0533267A, intermediate 42) (50 mg, 0.22 mmol) and 5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl chloride (62 mg, 0.22 mmol) using the method of Example 1 (49 mg, 44%) MH⁺=470/472.

Example 120

Naphthalene-2-sulfonic acid [4-bromo-3-(4-methylpiperazin-1-yl)phenyl]amide (E120)

15 [0080] The title compound (E120) was prepared from 4-bromo-3-(4-methylpiperazin-1-yl)benzenamine (EP 0533267A, intermediate 61) (600 mg, 2.23 mmol) and naphthalene-2-sulfonyl chloride (504 mg, 2.23 mmol) using the method of Example 1 (939 mg, 92%) MH⁺=460/462.

Example 123

20 **1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-6-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indole (E123)**

[0081] The title compound (E123) was prepared from 6-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indole (prepared from 3-nitroaniline, using methodology of WO95/06637 Intermediate 3) (39 mg, 0.18 mmol) and 5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl chloride (50 mg; 0.18 mmol) using the method of Example 1 (75 mg, 84%) MH⁺=462/464.

Example 124

30 **1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-5-methoxy-6-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indole (E124)**

[0082] The title compound (E124) was prepared from 5-methoxy-6-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indole (WO95/06637 intermediate 3) (99 mg, 0.4 mmol) and 5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl chloride (113 mg, 0.4 mmol) using the method of Example 1 (194 mg, 92%) MH⁺=492/494.

Example 125

40 **5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid[4-methoxy-2-methyl-3-(4-methylpiperazin-1-yl)phenyl] amide (E125)**

[0083] The title compound (E125) was prepared from 4-methoxy-2-methyl-3-(4-methylpiperazin-1-yl)phenylamine (D33) (58 mg, 0.247 mmol) and 5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl chloride (70 mg, 0.247 mmol) using the method of Example 1 (103 mg, 81%). MH⁺=480/482.

Example 126

5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid[2-(2-hydroxyethyl)-4-methoxy-3-(4-methylpiperazin-1-yl) phenyl]amide (E126)

50 [0084] The title compound (E126) was prepared from 2-[6-amino-3-methoxy-2-(4-methylpiperazin-1-yl)phenyl]ethanol (D32) (74mg, 0.28 mmol) and 5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl chloride (78 mg, 0.28 mmol) using the method of Example 1 (18 mg, 13%). MH⁺=510.

55

Example 127**1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-5-methoxy-4-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-Indole hydrochloride (E127)**

[0085] A mixture of 5-chloro-3-methylbenzo[b]thiophene-2-sulfonic acid[2-(2-hydroxyethyl)-4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]amide (E126) (218 mg, 0.25 mmol) and triphenyl phosphine (183 mg, 0.375 mmol) in dry THF (5 ml) under argon, was treated with a solution of diethyl azodicarboxylate (110 mg, 0.375 mmol) in dry THF (5 ml). The mixture was stirred overnight at room temperature. The solvent was evaporated under reduced pressure, and the residue partitioned between dilute hydrochloric acid and ethyl acetate. The acidic layer was basified with 40% sodium hydroxide and re-extracted with ethyl acetate. The organic phase was dried (Na_2SO_4) and evaporated under reduced pressure to give the crude product, which was purified by chromatography on silica gel, eluting with methanol and dichloromethane and the hydrochloride salt was formed (52 mg, 23%) $\text{MH}^+=492/494$.

Example 128**5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amide (E128)**

[0086] A solution of 3-methoxy-4-(4-methylpiperazin-1-yl)phenylamine (D35) (50 mg, 0.23 mmol) and 5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl chloride (64 mg, 0.23 mmol) in dichloromethane (2 ml) was allowed to stand at room temperature overnight. The reaction mixture was diluted with dichloromethane and washed with potassium carbonate (aq), which was back-extracted with further dichloromethane. The combined organic phases were dried (Na_2SO_4) and evaporated under reduced pressure to give a crude product, which was purified by chromatography on silica gel, eluting with methanol and dichloromethane. This gave the title compound (E128) as an off-white solid (36 mg, 34%) $\text{MH}^+=466$.

Example 132**Naphthalene-2-sulfonic acid [3-(4-methylpiperazin-1-yl)phenyl]amide (E132)**

[0087] The title compound (E132) was prepared from 3-(4-methylpiperazin-1-yl)benzenamine and naphthalene-2-sulfonyl chloride according to the method of Example 1 $\text{MH}^+=382$.

Preparation of aryl-N-(4-methoxy-3-piperazin-1-yl)-benzenesulfonamide hydrochlorides on solid phase (Examples 133-137)

[0088] The resin from Description 42 was stirred for 24h at room temperature with a solution of 1-chloroethylchloroformate (1.1mmol) in dichloromethane (2ml) then filtered and washed with dichloromethane. The filtrate was concentrated and the residue redissolved in methanol (3ml) and the solution refluxed for 5h. The solution was then concentrated to yield the title compound.

[0089] The following compounds were prepared as described above:

compound	MH^+
2,3,4-Trichloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)benzenesulfonamide (E133)	450/452
2,3-Dichloro-N-(4-methoxy-3-piperazin-1-yl-phenyl) benzenesulfonamide (E134)	416/418
3-Chloro-2-methyl-N-(4-methoxy-3-piperazin-1-yl-phenyl) benzenesulfonamide (E135)	396/398
4-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl) benzenesulfonamide (E136)	382/384
5-Bromo-thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-yl-phenyl)-amide (E137)	432/434

Example 138

[0090] 2,3-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide (E138) $\text{MS}(\text{MH}^+)$ 430/432 was prepared according to the general method of Example 1

Examples 139-141

[0091] The following compounds were prepared in an analogous way to Examples 68-75

	MS(MH ⁺)
1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-5-phenyl-6-piperazin-1-yl-2,3-dihydro-1H-indole (E139)	524/526
5-Chloro-1-(5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-6-piperazin-1-yl-2,3-dihydro-1H-indole (E140)	482/484
1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-7-piperazin-1-yl-1,2,3,4-tetrahydroquinoline (E141)	462/464

Example 142

5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid[4-methyl-3-(4-methylpiperazin-1-yl)phenyl]amide (E142)

[0092] The title compound (E142) was prepared from 5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl chloride and 4-methyl-3-(4-methylpiperazin-1-yl)benzenamine according to the method of Example 1 MH⁺ = 448/450.

[0093] Method for assay of 5-HT₆ antagonistic activity:

[0094] The test compounds were dissolved in polyethylene glycol:dimethyl sulfoxide (1:1) at 1 or 10mM and diluted to 0.1mM using 5mM tris buffer (pH 7.7 @ 25°C). Dissolution was assisted by addition of 0.02ml 5M HCl plus heating to 40°C and sonication for 10 minutes. Serial dilutions of drugs in the same buffer were carried out using either a TECAN 5052 or Biomek 2000 Workstation. Samples of the diluted test compounds (0.05ml) were mixed with 0.05ml of radio-ligand [³H]-LSD prepared in the incubation buffer, and 0.4ml of a suspension of a preparation of the washed membranes of HeLa_5HT₆ cells (acquired from Dr. D. Sibley, NIH, Bethesda, see Ref 1)(see Table 1), also in the incubation buffer. The details of the incubation conditions for each assay are shown in Table 2. The incubation buffer was 50mM Trizma (Sigma, UK) pH7.7 @ 25°C, 4mM MgCl₂.

[0095] After incubation at 37°C, the mixtures were filtered using a Packard Filtermate in Packard TopCount format. Filters were washed with 4 x 1ml aliquots of ice-cold incubation buffer. Filters were dried and impregnated with 0.04ml of Microscint 20 (Packard). IC₅₀ values were estimated from the counts per minute using a four parameter logistic curve fit within EXCEL (2). K_i values were calculated using the method of Cheng and Prusoff (3). pIC₅₀ and pK_i are the negative log 10 of the molar IC₅₀ and K_i respectively.

Table 1

Details of the methods used to prepare membranes for binding assays				
1st resuspension cells/ml	spin / resuspension 1, 2, 3	Incubation before final spin	protein conc. in stored aliquots	cells/ml in stored aliquots
7 x 10 ⁷	Yes	20min at 37°C	4mg/ml	1.0 x 10 ⁸

Table 2

Summary of receptor binding assay conditions				
protein (ug/ sample)	radio-ligand [³ H]-LSD (nM)	Specific Activity (Ci/ mmol)	Non-Specific Definition	Kd (nM)
40	2.0	83	Methiothepin	3.1

References

[0096]

1. MONSMA, F.J., SHEN, Y., WARD, R.P., HAMBLIN, M.W., SIBLEY, D.R.. 1993. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. *Mol. Pharmacol.*, **43**, 320-327.


2. BOWEN, W.P., JERMAN, J.C.. 1995. Nonlinear regression using spreadsheets. *Trends in Pharmacol. Sci.*, **16**, 413-417.

3. CHENG, Y.C., PRUSSOF, W.H.. 1973. Relationship between inhibition constant (K_i) and the concentration of inhibitor which causes 50% inhibition (IC_{50}) of an enzymatic reaction. *Biochem. Pharmacol.*, **92**, 881-894.

[0097] The compounds of Examples 11, 15, 17, 61, 65, 70, 72, 77, 78, 79, 83, 84, 87 and 90 all showed particularly good selective 5-HT₆ receptor antagonist activity, having pK_i values above 8.0 at human cloned 5-HT₆ receptors.

Claims

1. A compound of formula (I) or a salt thereof:



(I)

wherein:

P is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur;

A is a single bond, a C_{1-6} alkylene or a C_{1-6} alkenylene group;

R^1 is halogen, C_{1-6} alkyl optionally substituted by one or more halogen atoms, C_{3-6} cycloalkyl, COC_{1-6} alkyl, C_{1-6} alkoxy, OCF_3 , hydroxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkoxy, nitro, amino, C_{1-6} alkylamino or di C_{1-6} alkylamino, cyano or R^1 is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur;

n is 0, 1, 2, 3, 4, 5 or 6;

R^2 is hydrogen, C_{1-6} alkyl or aryl C_{1-6} alkyl;

R^3 is a group R^5 or together with R^5 forms a group $(CH_2)_2O$ or $(CH_2)_3O$ or R^3 is linked to R^2 to form a group $(CH_2)_2$ or $(CH_2)_3$;

R^4 is an N-piperazine ring optionally substituted by C_{1-6} alkyl; and

R^5 is hydrogen, halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, COC_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, hydroxy C_{1-6} alkyl, hydroxy C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkoxy, nitro, trifluoromethyl, cyano or aryl;

wherein aryl represents phenyl or naphthyl.

2. A compound according to claim 1 in which P is phenyl, thiophene, benzothiophene or naphthyl.

3. A compound according to claim 1 or 2 in which R^1 is halogen or C_{1-6} alkyl optionally substituted by one or more halogen atoms.

4. A compound according to any one of claims 1 to 3 in which R^2 is hydrogen.

5. A compound according to any one of claims 1 to 4 in which R^4 is an unsubstituted piperazine ring.

6. A compound according to any one of claims 1 to 5 in which R^5 is C_{1-6} alkoxy.

7. A compound according to any one of claims 1 to 6 in which R^5 is para with respect to the sulphonamide linkage.

8. A compound according to any one of claims 1 to 7 in which $P-A$ is 5-chloro-3-methyl-benzo[2]thiophen-2-yl.

9. A compound according to claim 1 which is:


4-Bromo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-5-(pyridin-2-yl)-2-thiophenesulfonamide,
 2,5-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-thiophenesulfonamide,
 4-Bromo-5-chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3-Bromo-5-chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzylsulfonamide,
 2-Bromo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3-Bromo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-methylbenzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-*trans*-styrenesulfonamide,
 3,4-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3,5-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-[2,1,3]benzothiadiazole-4-sulfonamide,
 5-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methyl-2-benzothiophenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methyl-5-nitrobenzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-trifluoromethylbenzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-trifluoromethylbenzenesulfonamide,
 2,5-Dimethoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-benzenesulfonamide,
 4-Fluoro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-Iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-Ethyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-*tert*-Butyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-Isopropyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-*tert*-Amyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-trifluoromethoxybenzenesulfonamide,
 4-*n*-Butoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-methylbenzenesulfonamide,
 5-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1-naphthalenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-naphthalenesulfonamide,
 5-(Dimethylamino)-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1-naphthalenesulfonamide,
 4-Bromo-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide,
 4-Methoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-*n*-Butyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-Amino-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 2-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 2,3,4-Trichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2,5-dimethylbenzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methylbenzenesulfonamide,
 2,5-Dibromo-3,6-difluoro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2,3,5,6-tetramethylbenzenesulfonamide,
 5-Chloro-2-methoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3-Fluoro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3,4-Difluoro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 4-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-nitrobenzenesulfonamide,
 3-Chloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methylbenzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-8-quinolinesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-phenylbenzenesulfonamide,
 3,4-Dimethoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3,5-dimethyl-4-isoxazolesulfonamide,
 4-Bromo-N-[4-methoxy-3-(4-ethylpiperazin-1-yl)phenyl]benzenesulfonamide,
 2,3-Dichloro-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,

5-Iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methylbenzenesulfonamide,
 3-Iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide,
 3-Iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-methylbenzenesulfonamide,
 5-Chloronaphthalene-2-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 5-Chloronaphthalene-1-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 4-Chloronaphthalene-1-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 7-Chloronaphthalene-1-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 5-Chloro-2-methylbenzo[b]thiophene-3-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 Benzofuran-2-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 1-Methyl-1H-indole-2-sulfonic acid [4-methoxy-3-(4-methylpiperazin-1-yl)phenyl] amide,
 5-Pyridin-2-ylthiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide, N-(4-Methoxy-3-piperazin-
 1-ylphenyl)-3-trifluoromethylbenzenesulfonamide,
 3-Iodo-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 3,5-Dimethylisoxazole-4-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 3,5-Dichloro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 2,5-Dibromo-3,6-difluoro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 Naphthalene-1-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 2-Bromo-5-chlorothiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 2-Chloro-4-fluoro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 3-Bromo-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 3-Chloro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 5-Chloronaphthalene-2-sulfonic acid(4-methoxy-3-piperazin-1-ylphenyl)amide,
 4-Bromo-5-chlorothiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 2,5-Dichlorothiophene-3-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide
 4-Bromo-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 5-Chloro-2-methylbenzo[b]thiophene-3-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 1-Methyl-1H-indole-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 Benzofuran-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide,
 Naphthalene-2-sulfonic acid(4-methoxy-3-piperazin-1-ylphenyl)amide,
 5-Chloronaphthalene-1-sulfonic acid(4-methoxy-3-piperazin-1-ylphenyl)amide,
 4-Chloro-2,5-dimethyl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 3,4-Dichloro-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 3-Chloro-N-(4-methoxy-3-piperazin-1-ylphenyl)-4-methyl-benzenesulfonamide,
 2-Trifluoromethyl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 4-Iodo-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 4-Tert-butyl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzenesulfonamide,
 Naphthalene-1-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 Thiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 5-Chlorothiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 5-Pyridin-2-ylthiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 2,5-Dichlorothiophene-3-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 4-Bromo-5-chlorothiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 3-Bromo-5-chlorothiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide,
 4-Chloro-2,5-dimethyl-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]
 amide,
 Naphthalene-2-sulfonic acid [7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl] amide.
 3-Bromo-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide,
 3,5-Dichloro-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide,
 4-Tert-Butyl-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide,
 2,5-Dibromo-3,6-difluoro-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzenesulfonamide,
 2,5-Dibromo-3,6-difluoro-N-(7-piperazin-1-yl-2,3-dihydrobenzofuran-5-yl)benzenesulfonamide,
 4-Chloro-2,5-dimethyl-N-(7-piperazin-1-yl-2,3-dihydrobenzofuran-5-yl)benzenesulfonamide,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulphonic acid [4-hydroxy-3-(4-methylpiperazin-1-yl)-phenyl]-amide,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulphonic acid [4-ethoxy-3-(4-methylpiperazin-1-yl)-phenyl]-amide,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulphonic acid [4-isopropoxy-3-(4-methylpiperazin-1-yl)-phenyl]-
 amide,

- Naphthalene-2-sulfonic acid [2-bromo-5-(4-methylpiperazin-1-yl)phenyl]amide,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [4-chloro-3-(4-methylpiperazin-1-yl)phenyl]amide,
 Naphthalene-2-sulfonic acid [4-bromo-3-(4-methylpiperazin-1-yl)phenyl]amide,
 1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-6-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indole,
 1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-5-methoxy-6-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indole,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [4-methoxy-2-methyl-3-(4-methylpiperazin-1-yl)phenyl]amide,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [2-(2-hydroxyethyl)-4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]amide,
 1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-5-methoxy-4-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indole hydrochloride,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amide,
 Naphthalene-2-sulfonic acid [3-(4-methylpiperazin-1-yl)phenyl]amide,
 2,3,4-Trichloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)benzenesulfonamide,
 2,3-Dichloro-N-(4-methoxy-3-piperazin-1-yl-phenyl) benzenesulfonamide,
 3-Chloro-2-methyl-N-(4-methoxy-3-piperazin-1-yl-phenyl) benzenesulfonamide,
 4-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl) benzenesulfonamide,
 5-Bromo-thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-yl-phenyl)-amide,
 2,3-Dichloro-N-(4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)-benzenesulfonamide,
 1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-5-phenyl-6-piperazin-1-yl-2,3-dihydro-1H-indole,
 5-Chloro-1-(5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-6-piperazin-1-yl-2,3-dihydro-1H-indole,
 1-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-7-piperazin-1-yl-1,2,3,4-tetrahydroquinoline,
 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid [4-methyl-3-(4-methylpiperazin-1-yl)phenyl]amide,


and pharmaceutically acceptable salts thereof.

10. A compound according to any one of claims 1 to 8 which is 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-ylphenyl) amide hydrochloride.
 11. A compound according to any one of claims 1 to 10 for use in therapy.
 12. A compound according to any one of claims 1 to 10 for use in therapy, in which the beneficial activity is effected by antagonism of 5-HT₆ receptors.
 13. A compound according to any one of claims 1 to 10 for use in the treatment of schizophrenia, Alzheimer's disease and/or depression.
 14. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 10 and a pharmaceutically acceptable carrier or excipient.
 15. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment of schizophrenia, Alzheimer's disease and/or depression.
 16. A process for the preparation of a compound of formula (I) or a salt thereof as defined in claim 1 which comprises the coupling of a compound of formula (II):



(II)

in which R¹, n, P, and A are as defined in formula (I) or protected derivatives thereof and L is a leaving group with a compound of formula (III):




(III)

in which R^2 , R^3 , R^4 and R^5 are as defined in formula (I) or protected derivatives thereof and optionally thereafter:

- removing any protecting groups,
- interconverting compounds of formula (I) wherein R^4 represents NH-piperazine to compounds of formula (I) wherein R^4 represents N- C_{1-6} alkyl-piperazine by alkylation,
- forming a pharmaceutically acceptable salt.

Patentansprüche

1. Verbindung der Formel (I) oder ein Salz davon:



(I)

wobei:

P eine Phenyl-, Naphthylgruppe, ein bicyclischer heterocyclischer Ring ist, oder ein 5- bis 7- gliedriger heterocyclischer Ring ist, welcher jeweils 1 bis 4 aus Sauerstoff, Stickstoff oder Schwefel ausgewählte Heteroatome enthält;

A eine Einfachbindung, ein C_{1-6} Alkyl- oder ein C_{1-6} -Alkenylenrest ist;

R^1 ein Halogenatom, ein gegebenenfalls durch ein oder mehrere Halogenatome substituierter C_{1-6} -Alkylrest, ein C_{3-6} -Cycloalkyl-, COC_{1-6} -Alkyl-, C_{1-6} -Alkoxyrest, eine OCF_3 -, Hydroxygruppe, ein Hydroxy- C_{1-6} -alkyl-, Hydroxy- C_{1-6} alkoxy-, C_{1-6} -Alkoxy- C_{1-6} -alkoxyrest, eine Nitro-, Aminogruppe, ein C_{1-6} -Alkylamino- oder Di- C_{1-6} -alkylaminorest, eine Cyanogruppe ist, oder R^1 eine Phenyl-, Naphthylgruppe, ein bicyclischer heterocyclischer Ring ist, oder ein 5- bis 7- gliedriger heterocyclischer Ring ist, welcher jeweils 1 bis 4 aus Sauerstoff, Stickstoff oder Schwefel ausgewählte Heteroatome enthält;

n gleich 0, 1, 2, 3, 4, 5 oder 6 ist;

R^2 ein Wasserstoffatom, ein C_{1-6} Alkyl- oder Aryl- C_{1-6} -alkylrest ist;

R^3 ein Rest R^5 ist, oder zusammen mit R^5 eine Gruppe $(CH_2)_2O$ oder $(CH_2)_3O$ bildet, oder R^3 mit R^2 verbunden ist, um eine Gruppe $(CH_2)_2$ oder $(CH_2)_3$ zu bilden;

R^4 ein gegebenenfalls durch einen C_{1-6} Alkylrest substituierter N-Piperazinring ist; und

R⁵ ein Wasserstoff-, Halogenatom, ein C₁₋₆-Alkyl-, C₃₋₆-Cycloalkyl-, COC₁₋₆-Alkyl-, C₁₋₆-Alkoxyrest, eine Hydroxygruppe, ein Hydroxy-C₁₋₆-alkyl-, Hydroxy-C₁₋₆-alkoxy-, C₁₋₆-Alkoxy-C₁₋₆-alkoxyrest, eine Nitro-, Trifluor-methyl-, Cyanogruppe oder ein Arylrest ist;

5 wobei ein Arylrest eine Phenyl- oder Naphthylgruppe bedeutet.

2. Verbindung gemäß Anspruch 1, wobei P eine Phenyl-, Thiophen-, Benzothiophen- oder Naphthylgruppe ist.

3. Verbindung gemäß Anspruch 1 oder 2, wobei R¹ ein Halogenatom oder ein gegebenenfalls durch ein oder mehrere
10 Halogenatome substituierter C₁₋₆-Alkylrest ist.

4. Verbindung gemäß einem der Ansprüche 1 bis 3, wobei R² ein Wasserstoffatom ist.

5. Verbindung gemäß einem der Ansprüche 1 bis 4, wobei R⁴ ein unsubstituierter Piperazinring ist.
15

6. Verbindung gemäß einem der Ansprüche 1 bis 5, wobei R⁵ ein C₁₋₆-Alkoxyrest ist.

7. Verbindung gemäß einem der Ansprüche 1 bis 6, wobei sich R⁵ in para-Stellung bezüglich der Sulfonamidbindung
20 befindet.

8. Verbindung gemäß einem der Ansprüche 1 bis 7, wobei P-A 5-Chlor-3-methylbenzo[2]thiophen-2-yl ist.

9. Verbindung gemäß Anspruch 1, nämlich:

25 4-Brom-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophensulfonamid,
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-5-(pyridin-2-yl)-2-thiophensulfonamid,
2,5-Dichlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-thiophensulfonamid,
30 4-Brom-5-chlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophensulfonamid,
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
3-Brom-5-chlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophensulfonamid,
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzylsulfonamid,
2-Brom-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
35 3-Brom-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
3-Chlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-methyl-benzolsulfonamid,
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-*trans*-styrolsulfonamid,
3,4-Dichlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
3,5-Dichlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
40 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-[2,1,3]benzothiadiazol-4-sulfonamid,
5-Chlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methyl-2-benzothiophensulfonamid,
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methyl-5-nitro-benzolsulfonamid,
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-trifluormethyl-benzolsulfonamid,
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-trifluormethyl-benzolsulfonamid,
45 2,5-Dimethoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
4-Fluor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
4-Chlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
4-Iod-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
4-Ethyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
50 4-*tert*-Butyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
4-Isopropyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
4-*tert*-Amyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-trifluormethoxy-benzolsulfonamid,
4-n-Butoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-methylbenzolsulfonamid,
55 5-Chlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-thiophensulfonamid,
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1-naphthalinsulfonamid,
N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-naphthalinsulfonamid,
5-(Dimethylamino)-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1-naphthalinsulfonamid,

4-Brom-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzolsulfonamid,
 4-Methoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 4-n-Butyl-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 4-Amino-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 5 2-Chlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 3-Chlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 2,3,4-Trichlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 4-Chlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2,5-dimethyl-benzolsulfonamid,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-methylbenzolsulfonamid,
 10 2,5-Dibrom-3,6-difluor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2,3,5,6-tetramethyl-benzolsulfonamid,
 5-Chlor-2-methoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 3-Fluor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 4-Difluor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 15 4-Chlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3-nitro-benzolsulfonamid,
 3-Chlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methyl-benzolsulfonamid,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-8-chinolinsulfonamid,
 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-phenylbenzolsulfonamid,
 3,4-Dimethoxy-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 20 N-[4-Methoxy-3-(4-methylpiperazin-1-yl)phenyl]-3,5-dimethyl-4-isoxazolsulfonamid,
 4-Brom-N-[4-methoxy-3-(4-ethylpiperazin-1-yl)phenyl]benzolsulfonamid,
 2,3-Dichlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 5-Iod-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-2-methyl-benzolsulfonamid,
 3-Iod-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 25 3-Iod-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-methyl-benzolsulfonamid,
 5-Chlor-naphthalin-2-sulfonsäure-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]amid,
 5-Chlor-naphthalin-1-sulfonsäure-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]amid,
 4-Chlor-naphthalin-1-sulfonsäure-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]amid,
 7-Chlor-naphthalin-1-sulfonsäure-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]amid,
 30 5-Chlor-2-methylbenzo[b]thiophen-3-sulfonsäure-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]amid,
 Benzofuran-2-sulfonsäure-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]amid,
 1-Methyl-1H-indol-2-sulfonsäure-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]amid,
 5-Pyridin-2-ylthiophen-2-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid,
 N-(4-Methoxy-3-piperazin-1-ylphenyl)-3-trifluormethyl-benzolsulfonamid, ..
 35 3-Iod-N-(4-methoxy-3-piperazin-1-ylphenyl)benzolsulfonamid,
 3,5-Dimethylisoxazol-4-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid,
 3,5-Dichlor-N-(4-methoxy-3-piperazin-1-ylphenyl)benzolsulfonamid,
 2,5-Dibrom-3,6-difluor-N-(4-methoxy-3-piperazin-1-ylphenyl)benzolsulfonamid,
 Naphthalin-1-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid,
 40 3-Brom-5-chlor-thiophen-2-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid,
 2-Chlor-4-fluor-N-(4-methoxy-3-piperazin-1-ylphenyl)benzolsulfonamid,
 3-Brom-N-(4-methoxy-3-piperazin-1-ylphenyl)benzolsulfonamid,
 3-Chlor-N-(4-methoxy-3-piperazin-1-ylphenyl)benzolsulfonamid,
 5-Chlor-naphthalin-2-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid,
 45 4-Brom-5-chlorthiophen-2-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid,
 2,5-Dichlorthiophen-3-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid,
 4-Brom-N-(4-methoxy-3-piperazin-1-ylphenyl)benzolsulfonamid,
 5-Chlor-3-methylbenzo[b]thiophen-2-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid,
 5-Chlor-3-methylbenzo[b]thiophen-3-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid,
 50 1-Methyl-1H-indol-2-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid,
 Benzofuran-2-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid,
 Naphthalin-2-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid,
 5-Chlor-naphthalin-1-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amid, ..
 4-Chlor-2,5-dimethyl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzolsulfonamid,
 55 3,4-Dichlor-N-(4-methoxy-3-piperazin-1-ylphenyl)benzolsulfonamid,
 3-Chlor-N-(4-methoxy-3-piperazin-1-ylphenyl)-4-methyl-benzolsulfonamid,
 2-Trifluormethyl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzolsulfonamid,
 4-Iod-N-(4-methoxy-3-piperazin-1-ylphenyl)benzolsulfonamid,

- 4-*tert*-Butyl-N-(4-methoxy-3-piperazin-1-ylphenyl)benzolsulfonamid,
 Naphthalin-1-sulfonsäure-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]amid,
 Thiophen-2-sulfonsäure-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]amid,
 5-Chlorthiophen-2-sulfonsäure-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]amid,
 5-Pyridin-2-ylthiophen-2-sulfonsäure-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]amid
 2,5-Dichlorthiophen-3-sulfonsäure-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]amid,
 4-Brom-5-chlorthiophen-2-sulfonsäure-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]amid,
 3-Brom-5-chlorthiophen-2-sulfonsäure-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]amid,
 4-Chlor-2,5-dimethyl-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzolsulfonamid,
 5-Chlor-3-methylbenzo[b]thiophen-2-sulfonsäure-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]
 amid,
 Naphthalin-2-sulfonsäure-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]amid,
 3-Brom-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzolsulfonamid,
 3,5-Dichlor-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzolsulfonamid,
 4-*tert*-Butyl-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzolsulfonamid,
 2,5-Dibrom-3,6-difluor-N-[7-(4-methylpiperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzolsulfonamid,
 2,5-Dibrom-3,6-difluor-N-(7-piperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzolsulfonamid,
 4-Chlor-2,5-dimethyl-N-(7-piperazin-1-yl)-2,3-dihydrobenzofuran-5-yl]benzolsulfonamid,
 5-Chlor-3-methylbenzo[b]thiophen-2-sulfonsäure-[4-hydroxy-3-(4-methylpiperazin-1-yl)phenyl]amid,
 5-Chlor-3-methylbenzo[b]thiophen-2-sulfonsäure-[4-ethoxy-3-(4-methylpiperazin-1-yl)phenyl]amid,
 5-Chlor-3-methylbenzo[b]thiophen-2-sulfonsäure-[4-isopropoxy-3-(4-methylpiperazin-1-yl)phenyl]amid,
 Naphthalin-2-sulfonsäure-[2-brom-5-(4-methylpiperazin-1-yl)phenyl]amid,
 5-Chlor-3-methylbenzo[b]thiophen-2-sulfonsäure-[4-chlor-3-(4-methylpiperazin-1-yl)phenyl]amid,
 Naphthalin-2-sulfonsäure-[4-brom-3-(4-methylpiperazin-1-yl)phenyl]amid,
 1-(5-Chlor-3-methylbenzo[b]thiophen-2-sulfonyl)-6-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indol,
 1-(5-Chlor-3-methylbenzo[b]thiophen-2-sulfonyl)-5-methoxy-6-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-in-
 dol,
 5-Chlor-3-methylbenzo[b]thiophen-2-sulfonsäure-[4-methoxy-2-methyl-3-(4-methylpiperazin-1-yl)phenyl]
 amid,
 5-Chlor-3-methylbenzo[b]thiophen-2-sulfonsäure-[2-(2-hydroxyethyl)-4-methoxy-3-(4-methylpiperazin-1-yl)
 phenyl]amid,
 1-(5-Chlor-3-methylbenzo[b]thiophen-2-sulfonyl)-5-methoxy-4-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-in-
 dolhydrochlorid,
 5-Chlor-3-methylbenzo[b]thiophen-2-sulfonsäure-[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amid,
 Naphthalin-2-sulfonsäure-[3-(4-methylpiperazin-1-yl)phenyl]amid,
 2,3,4-Trichlor-N-(4-methoxy-3-piperazin-1-yl-phenyl)benzolsulfonamid,
 2,3-Dichlor-N-(4-methoxy-3-piperazin-1-yl-phenyl)benzolsulfonamid,
 3-Chlor-2-methyl-N-(4-methoxy-3-piperazin-1-yl-phenyl)benzolsulfonamid,
 4-Chlor-N-(4-methoxy-3-piperazin-1-yl-phenyl)benzolsulfonamid,
 5-Brom-thiophen-2-sulfonsäure-(4-methoxy-3-piperazin-1-yl-phenyl)amid,
 2,3-Dichlor-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzolsulfonamid,
 1-(5-Chlor-3-methylbenzo[b]thiophen-2-sulfonyl)-5-phenyl-6-piperazin-1-yl-2,3-dihydro-1H-indol,
 5-Chlor-1-(5-chlor-3-methylbenzo[b]thiophen-2-sulfonyl)-6-piperazin-1-yl-2,3-dihydro-1H-indol,
 1-(5-Chlor-3-methylbenzo[b]thiophen-2-sulfonyl)-7-piperazin-1-yl-1,2,3,4-tetrahydrochinolin,
 5-Chlor-3-methylbenzo[b]thiophen-2-sulfonsäure-[4-methyl-3-(4-methylpiperazin-1-yl)-phenyl]amid,

und pharmazeutisch verträgliche Salze davon.


10. Verbindung gemäß einem der Ansprüche 1 bis 8, nämlich
 5-Chlor-3-methylbenzo[b]thiophen-2-sulfonsäure-(4-methoxy-3-piperazin-1-ylphenyl)amidhydrochlorid.
 11. Verbindung gemäß einem der Ansprüche 1 bis 10 zur Verwendung in der Therapie.
 12. Verbindung gemäß einem der Ansprüche 1 bis 10 zur Verwendung in der Therapie, wobei die heilsame Wirkung
 durch Antagonismus der 5-HT₆-Rezeptoren bewirkt wird.
 13. Verbindung gemäß einem der Ansprüche 1 bis 10 zur Verwendung zur Behandlung von Schizophrenie, Alzheimer
 und/oder Depression.

14. Arzneimittel, welches eine Verbindung nach einem der Ansprüche 1 bis 10 und einen pharmazeutisch verträglichen Träger oder Exzipienten umfasst.

15. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 10 zur Herstellung eines Medikaments zur Behandlung von Schizophrenie, Alzheimer und/oder Depression.


16. Verfahren zur Herstellung einer Verbindung der Formel (I) oder eines Salzes davon nach Anspruch 1, welches umfasst:

Kuppeln einer Verbindung der Formel (II):



(II)

wobei R^1 , n , P und A wie in Formel (I) definiert oder geschützte Derivate davon sind, und L eine Abgangsgruppe ist, mit einer Verbindung der Formel (III):



(III)

wobei R^2 , R^3 , R^4 und R^5 wie in Formel (I) definiert sind oder geschützte Derivate davon sind und gegebenenfalls nachfolgend:


Entfernen jeglicher Schutzgruppen,

Umwandeln von Verbindungen der Formel (I), in welchen R^4 einen NH-Piperazinrest bedeutet, in Verbindungen der Formel (I), in welchen R^4 einen N- C_{1-6} -Alkyl-Piperazinrest bedeutet, durch Alkylieren,

Bilden eines pharmazeutisch verträglichen Salzes davon.

Revendications

1. Composé de formule (I) ou un de ses sels :



(I)

formule dans laquelle :

P représente un groupe phényle, un groupe naphthyle, un noyau hétérocyclique bicyclique ou un noyau hétérocyclique penta- à heptagonal, chacun contenant 1 à 4 hétéroatomes choisis entre l'oxygène, l'azote et le

soufre ;

A représente une liaison simple, un groupe alkylène en C₁ à C₆ ou alcénylène en C₁ à C₆ ;

R¹ représente un atome d'halogène, un groupe alkyle en C₁ à C₆ facultativement substitué avec un ou plusieurs atomes d'halogène, cycloalkyle en C₃ à C₆, CO(alkyle en C₁ à C₆), alkoxy en C₁ à C₆, OCF₃, hydroxy, hydroxyalkyle en C₁ à C₆, hydroxyalkoxy en C₁ à C₆, (alkoxy en C₁ à C₆) (alkoxy en C₁ à C₆), nitro, amino, alkylamino en C₁ à C₆ ou di(alkyle en C₁ à C₆)amino, cyano, ou bien R¹ représente un groupe phényle, un groupe naphthyle, un noyau hétérocyclique bicyclique ou un noyau hétérocyclique penta- à heptagonal, chacun contenant 1 à 4 hétéroatomes choisis entre l'oxygène, l'azote et le soufre ;

n est égal à 0, 1, 2, 3, 4, 5 ou 6 ;

R² représente un atome d'hydrogène, un groupe alkyle en C₁ à C₆ ou aryl(alkyle en C₁ à C₆) ;

R³ représente un groupe R⁵ ou, conjointement avec R⁵, forme un groupe (CH₂)₂O ou (CH₂)₃O, ou bien R³ est lié à R² pour former un groupe (CH₂)₂ ou (CH₂)₃ ;

R⁴ représente un noyau N-pipérazine facultativement substitué avec un substituant alkyle en C₁ à C₆ ; et

R⁵ représente un atome d'hydrogène, un atome d'halogène, un groupe alkyle en C₁ à C₆, cycloalkyle en C₃ à C₆, CO(alkyle en C₁ à C₆), alkoxy en C₁ à C₆, hydroxy, hydroxyalkyle en C₁ à C₆, hydroxyalkoxy en C₁ à C₆, (alkoxy en C₁ à C₆) (alkoxy en C₁ à C₆), nitro, trifluorométhyle, cyano ou aryle ;

le terme aryle représentant un groupe phényle ou naphthyle.

2. Composé suivant la revendication 1, dans lequel P représente un groupe phényle, thiophène, benzothiophène ou naphthyle.
3. Composé suivant la revendication 1 ou 2, dans lequel R¹ représente un atome d'halogène ou un groupe alkyle en C₁ à C₆ facultativement substitué avec un ou plusieurs atomes d'halogène.
4. Composé suivant l'une quelconque des revendications 1 à 3, dans lequel R² représente un atome d'hydrogène.
5. Composé suivant l'une quelconque des revendications 1 à 4, dans lequel R⁴ représente un noyau pipérazine non substitué.
6. Composé suivant l'une quelconque des revendications 1 à 5, dans lequel R⁵ représente un groupe alkoxy en C₁ à C₆.
7. Composé suivant l'une quelconque des revendications 1 à 6, dans lequel R⁵ est en position para par rapport à la liaison sulfonamide.
8. Composé suivant l'une quelconque des revendications 1 à 7, dans lequel P-A représente un groupe 5-chloro-3-méthylbenzo[2]thiophène-2-yle.
9. Composé suivant la revendication 1, qui consiste en :

4-bromo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-2-thiophènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-5-(pyridine-2-yl)-2-thiophènesulfonamide,
 2,5-dichloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-3-thiophènesulfonamide,
 4-bromo-5-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-2-thiophènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-benzènesulfonamide,
 3-bromo-5-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-2-thiophènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzylsulfonamide,
 2-bromo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 3-bromo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 3-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-4-méthylbenzènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-trans-styrènesulfonamide,
 3,4-dichloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 3,5-dichloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-[2,1,3]benzothiadiazole-4-sulfonamide,
 5-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-3-méthyl-2-benzothiophènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-2-méthyl-5-nitrobenzènesulfonamide,


N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-2-trifluorométhylbenzènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-3-trifluorométhylbenzènesulfonamide,
 2,5-diméthoxy-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzènesulfonamide,
 4-fluoro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 4-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 4-iodo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 4-éthyl-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 4-tertio-butyl-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 4-isopropyl-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 4-tertio-amyl-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-4-trifluorométhoxybenzènesulfonamide,
 4-n-butoxy-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-4-méthylbenzènesulfonamide,
 5-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-2-thiophènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-1-naphtalènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-2-naphtalènesulfonamide,
 5-(diméthylamino)-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-1-naphtalènesulfonamide,
 4-bromo-N-[7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
 4-méthoxy-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 4-n-butyl-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 4-amino-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 2-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 3-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 2, 3, 4-trichloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzènesulfonamide,
 4-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-2,5-diméthylbenzènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-3-méthylbenzènesulfonamide,
 2,5-dibromo-3,6-difluoro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-2,3,5,6-tétraméthylbenzènesulfonamide,
 5-chloro-2-méthoxy-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzènesulfonamide,
 3-fluoro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 3,4-difluoro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 4-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-3-nitrobenzènesulfonamide,
 3-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-2-méthylbenzènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-8-quinoléinesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-4-phénylbenzènesulfonamide,
 3,4-diméthoxy-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzènesulfonamide,
 N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-3,5-diméthyl-4-isoxazolesulfonamide,
 4-bromo-N-[4-méthoxy-3-(4-éthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 2,3-dichloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 5-iodo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-2-méthylbenzènesulfonamide,
 3-iodo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
 3-iodo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-4-méthylbenzènesulfonamide,
 [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloronaphtalène-2-sulfonique,
 [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloronaphtalène-1-sulfonique,
 [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 4-chloronaphtalène-1-sulfonique,
 [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 7-chloronaphtalène-1-sulfonique,
 [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-2-méthylbenzo[b]thiophène-3-sulfonique,
 [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide benzofuranne-2-sulfonique,
 [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 1-méthyl-1H-indole-2-sulfonique,
 [4-méthoxy-3-pipérazine-1-ylphényl]amide d'acide 5-pyridine-2-ylthiophène-2-sulfonique,
 N-(4-méthoxy-3-pipérazine-1-ylphényl)-3-trifluorométhylbenzènesulfonamide,
 3-iodo-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
 (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 3,5-diméthylisoxazole-4-sulfonique,
 3,5-dichloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
 2,5-dibromo-3,6-difluoro-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
 (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide naphtalène-1-sulfonique,
 (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 2-bromo-5-chlorothiophène-2-sulfonique,

2-chloro-4-fluoro-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
 3-bromo-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
 3-chloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
 (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 5-chloronaphtalène-2-sulfonique,
 (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 4-bromo-5-chlorothiophène-2-sulfonique,
 (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 2,5-dichlorothiophène-3-sulfonique,
 4-bromo-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
 (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
 (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 5-chloro-2-méthylbenzo[b]thiophène-3-sulfonique,
 (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 1-méthyl-1H-indole-2-sulfonique,
 (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide benzofuranne-2-sulfonique,
 (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide naphtalène-2-sulfonique,
 (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 5-chloronaphtalène-1-sulfonique,
 4-chloro-2,5-diméthyl-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
 3,4-dichloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
 3-chloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)-4-méthylbenzènesulfonamide,
 2-trifluorométhyl-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
 4-iodo-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
 4-tertio-butyl-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
 [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide naphtalène-1-sulfonique,
 [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide thiophène-2-sulfonique,
 [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide 5-chlorothiophène-2-sulfonique,
 [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide 5-pyridine-2-ylthiophène-2-sulfonique,
 [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide 2,5-dichlorothiophène-3-sulfonique,
 [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide 4-bromo-5-chlorothiophène-2-sulfonique,
 [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide 3-bromo-5-chlorothiophène-2-sulfonique,
 4-chloro-2,5-diméthyl-N-[7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
 [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
 [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide naphtalène-2-sulfonique,
 3-bromo-N-[7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
 3,5-dichloro-N-[7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
 4-tertio-butyl-N-[7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
 2,5-dibromo-3,6-difluoro-N-[7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
 2,5-dibromo-3,6-difluoro-N-(7-pipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
 4-chloro-2,5-diméthyl-N-(7-pipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
 [4-hydroxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
 [4-éthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
 [4-isopropoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
 [2-bromo-5-(4-méthylpipérazine-1-yl)phényl]amide d'acide naphtalène-2-sulfonique,
 [4-chloro-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
 [4-bromo-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide naphtalène-2-sulfonique,
 1-(5-chloro-3-méthylbenzo[b]thiophène-2-sulfonyl)-6-(4-méthylpipérazine-1-yl)-2,3-dihydro-1H-indole,
 1-(5-chloro-3-méthylbenzo[b]thiophène-2-sulfonyl)-5-méthoxy-6-(4-méthylpipérazine-1-yl)-2,3-dihydro-1H-indole,
 [4-méthoxy-2-méthyl-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
 [2-(2-hydroxyéthyl)-4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
 chlorhydrate de 1-(5-chloro-3-méthylbenzo[b]thiophène-2-sulfonyl)-5-méthoxy-4-(4-méthylpipérazine-1-yl)-

2,3-dihydro-1H-indole,
[3-méthoxy-4-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfon-
que,
[3-(4-méthylpipérazine-1-yl)phényl]amide d'acide naphthalène-2-sulfonique,
2,3,4-trichloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)-benzènesulfonamide,
2,3-dichloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)-benzènesulfonamide,
3-chloro-2-méthyl-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
4-chloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)-benzènesulfonamide,
(4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 5-bromothiophène-2-sulfonique,
2,3-dichloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
1-(5-chloro-3-méthylbenzo[b]thiophène-2-sulfonyl)-5-phényl-6-pipérazine-1-yl-2,3-dihydro-1H-indole,
5-chloro-1-(5-chloro-3-méthylbenzo[b]thiophène-2-sulfonyl)-6-pipérazine-1-yl-2,3-dihydro-1H-indole,
1-(5-chloro-3-méthylbenzo[b]thiophène-2-sulfonyl)-7-pipérazine-1-yl-1,2,3,4-tétrahydroquinoléine,
[4-méthyl-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfoni-
que,


et ses sels pharmaceutiquement acceptables.

10. Composé suivant l'une quelconque des revendications 1 à 8, qui est le chlorhydrate de (4-méthoxy-3-pipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique.
11. Composé suivant l'une quelconque des revendications 1 à 10, destiné à être utilisé en thérapeutique.
12. Composé suivant l'une quelconque des revendications 1 à 10, destiné à être utilisé en thérapeutique, dans lequel l'activité bénéfique se manifeste par un antagonisme des récepteurs 5-HT₆.
13. Composé suivant l'une quelconque des revendications 1 à 10, destiné à être utilisé dans le traitement de la schizophrénie, de la maladie d'Alzheimer et/ou de la dépression.
14. Composition pharmaceutique qui comprend un composé suivant l'une quelconque des revendications 1 à 10 et un support ou excipient pharmaceutiquement acceptable.
15. Utilisation d'un composé suivant l'une quelconque des revendications 1 à 10 dans la production d'un médicament destiné au traitement de la schizophrénie, de la maladie d'Alzheimer et/ou de la dépression.
16. Procédé pour la préparation d'un composé de formule (I) ou d'un de ses sels répondant à la définition suivant la revendication 1, qui comprend le couplage d'un composé de formule (II) :



(II)

dans laquelle R¹, n, P et A sont tels que définis dans la formule (I), ou leurs dérivés protégés, et L représente un groupe partant, avec un composé de formule (III) :



(III)

dans laquelle R², R³, R⁴ et R⁵ sont tels que définis dans la formule (I), ou leurs dérivés protégés, et ensuite, facultativement :

- l'élimination de tous les groupes protecteurs
- l'interconversion de composés de formule (I) dans laquelle R⁴ représente un groupe NH-pipérazine en composés de formule (I) dans laquelle R⁴ représente un groupe N-(alkyle en C₁ à C₆)pipérazine par alkylation,
- la formation d'un sel pharmaceutiquement acceptable.